CR20160361A - Benzimidazol-2-aminas como inhibidores de midh1 - Google Patents
Benzimidazol-2-aminas como inhibidores de midh1Info
- Publication number
- CR20160361A CR20160361A CR20160361A CR20160361A CR20160361A CR 20160361 A CR20160361 A CR 20160361A CR 20160361 A CR20160361 A CR 20160361A CR 20160361 A CR20160361 A CR 20160361A CR 20160361 A CR20160361 A CR 20160361A
- Authority
- CR
- Costa Rica
- Prior art keywords
- benzimidazol
- aminas
- midh1
- inhibitors
- midh1 inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical class C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14154680 | 2014-02-11 | ||
| EP14182002 | 2014-08-22 | ||
| PCT/EP2015/052676 WO2015121210A1 (en) | 2014-02-11 | 2015-02-10 | Benzimidazol-2-amines as midh1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20160361A true CR20160361A (es) | 2016-10-03 |
Family
ID=52462928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20160361A CR20160361A (es) | 2014-02-11 | 2015-02-10 | Benzimidazol-2-aminas como inhibidores de midh1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9957235B2 (enExample) |
| EP (1) | EP3105209B1 (enExample) |
| JP (1) | JP6534675B2 (enExample) |
| KR (1) | KR20160115991A (enExample) |
| CN (1) | CN106573897B (enExample) |
| AP (1) | AP2016009371A0 (enExample) |
| AU (1) | AU2015217788B2 (enExample) |
| BR (1) | BR112016018604A2 (enExample) |
| CA (1) | CA2939026A1 (enExample) |
| CL (1) | CL2016002033A1 (enExample) |
| CR (1) | CR20160361A (enExample) |
| CU (1) | CU24410B1 (enExample) |
| DO (1) | DOP2016000208A (enExample) |
| EA (1) | EA031655B1 (enExample) |
| IL (1) | IL246785A0 (enExample) |
| MX (1) | MX2016010474A (enExample) |
| PE (1) | PE20170143A1 (enExample) |
| PH (1) | PH12016501581A1 (enExample) |
| SG (1) | SG11201605810WA (enExample) |
| SV (1) | SV2016005257A (enExample) |
| TW (1) | TWI666202B (enExample) |
| UY (1) | UY35991A (enExample) |
| WO (1) | WO2015121210A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA031655B1 (ru) | 2014-02-11 | 2019-02-28 | Байер Фарма Акциенгезельшафт | Бензимидазол-2-амины в качестве ингибиторов midhi |
| ES2732902T3 (es) | 2014-02-11 | 2019-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Bencimidazol-2-aminas como inhibidores de MIDH1 |
| JP6648116B2 (ja) | 2014-09-19 | 2020-02-14 | フォーマ セラピューティクス，インコーポレイテッド | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物 |
| ES2953347T3 (es) | 2014-09-19 | 2023-11-10 | Forma Therapeutics Inc | Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante |
| WO2016062677A1 (en) * | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| CA2965213A1 (en) * | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors |
| EP3303302B1 (en) * | 2015-06-08 | 2019-03-20 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| WO2017005674A1 (en) | 2015-07-07 | 2017-01-12 | Bayer Pharma Aktiengesellschaft | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors |
| JP6824954B2 (ja) * | 2015-07-16 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール |
| EP3121166A1 (en) * | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| TW201708193A (zh) * | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑 |
| TW201718513A (zh) * | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法 |
| AU2017217536A1 (en) * | 2016-02-09 | 2018-08-09 | Inventisbio Inc. | Inhibitor of indoleamine-2,3-dioxygenase (IDO) |
| WO2019015672A1 (zh) * | 2017-07-21 | 2019-01-24 | 南京明德新药研发股份有限公司 | 吡啶并咪唑类化合物及其应用 |
| JP2020535112A (ja) * | 2017-08-01 | 2020-12-03 | ドイッチェス・クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ | Ｍｉｄｈ１阻害剤とｄｎａ低メチル化剤（ｈｍａ）との組合せ |
| PT3720442T (pt) | 2018-05-16 | 2023-03-13 | Forma Therapeutics Inc | Inibição de idh-1 mutante |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| JP7258059B2 (ja) * | 2018-06-26 | 2023-04-14 | 昆薬集団股▲フン▼有限公司 | ベンズイミダゾール誘導体及びそのｉｄｈ１阻害剤としての応用 |
| TWI760017B (zh) * | 2019-12-23 | 2022-04-01 | 大陸商昆藥集團股份有限公司 | 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| IL299859A (en) | 2020-07-21 | 2023-03-01 | Daiichi Sankyo Co Ltd | A combination drug of temozolomide and a mutant IDH1 enzyme inhibitor |
| CN112062687B (zh) * | 2020-09-02 | 2023-11-21 | 上海信谊万象药业股份有限公司 | 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| CN1161340C (zh) | 1998-11-30 | 2004-08-11 | 先灵公司 | 为玻连蛋白受体拮抗剂的苯并咪唑化合物 |
| US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
| WO2003007945A1 (en) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| MXPA04008458A (es) | 2002-03-01 | 2004-12-06 | Smithkline Beecham Corp | Diamino pirimidinas y su uso como inhibidores de angiogenesis. |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| JP4842829B2 (ja) | 2003-10-31 | 2011-12-21 | 武田薬品工業株式会社 | 含窒素縮合複素環化合物 |
| WO2005121132A1 (ja) | 2004-06-11 | 2005-12-22 | Shionogi & Co., Ltd. | 抗ｈｃｖ作用を有する縮合ヘテロ環化合物 |
| WO2006038738A1 (ja) | 2004-10-08 | 2006-04-13 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| US7893267B2 (en) | 2005-03-14 | 2011-02-22 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors |
| WO2008153701A1 (en) * | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| US8168800B2 (en) | 2007-11-02 | 2012-05-01 | The Regents Of The University Of California | Aβ-binding small molecules |
| WO2009116074A2 (en) | 2008-02-13 | 2009-09-24 | Cadila Healthcare Limited | Substituted benzimidazoles as cannabinoid modulator |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| EP2445345B1 (en) * | 2009-06-23 | 2014-08-27 | The Translational Genomics Research Institute | Benzamide derivatives |
| WO2011072174A1 (en) | 2009-12-09 | 2011-06-16 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| WO2012172043A1 (en) * | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN103435554A (zh) * | 2013-09-06 | 2013-12-11 | 中国药科大学 | 2-苯氨基苯并咪唑类化合物及其用途 |
| ES2732902T3 (es) | 2014-02-11 | 2019-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Bencimidazol-2-aminas como inhibidores de MIDH1 |
| EA031655B1 (ru) | 2014-02-11 | 2019-02-28 | Байер Фарма Акциенгезельшафт | Бензимидазол-2-амины в качестве ингибиторов midhi |
| WO2016062677A1 (en) | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| CA2965213A1 (en) | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors |
| EP3297437A4 (en) | 2015-05-18 | 2019-02-27 | Translational Drug Development Llc | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KINASES |
| JP7028765B2 (ja) | 2015-05-22 | 2022-03-02 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | ベンズアミドおよび活性化合物組成物および使用方法 |
| EP3303302B1 (en) | 2015-06-08 | 2019-03-20 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| WO2017005674A1 (en) | 2015-07-07 | 2017-01-12 | Bayer Pharma Aktiengesellschaft | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors |
| JP6824954B2 (ja) | 2015-07-16 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール |
| EP3121166A1 (en) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| TW201718513A (zh) | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法 |
| TW201708193A (zh) | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑 |
| JP6768078B2 (ja) | 2016-03-02 | 2020-10-14 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | アミノベンゾイミダゾール誘導体 |
-
2015
- 2015-02-10 EA EA201691590A patent/EA031655B1/ru not_active IP Right Cessation
- 2015-02-10 SG SG11201605810WA patent/SG11201605810WA/en unknown
- 2015-02-10 WO PCT/EP2015/052676 patent/WO2015121210A1/en not_active Ceased
- 2015-02-10 JP JP2016551221A patent/JP6534675B2/ja not_active Expired - Fee Related
- 2015-02-10 CN CN201580019265.9A patent/CN106573897B/zh not_active Expired - Fee Related
- 2015-02-10 KR KR1020167024825A patent/KR20160115991A/ko not_active Withdrawn
- 2015-02-10 CA CA2939026A patent/CA2939026A1/en not_active Abandoned
- 2015-02-10 US US15/118,154 patent/US9957235B2/en active Active
- 2015-02-10 PE PE2016001465A patent/PE20170143A1/es unknown
- 2015-02-10 CU CU2016000120A patent/CU24410B1/es unknown
- 2015-02-10 AP AP2016009371A patent/AP2016009371A0/en unknown
- 2015-02-10 MX MX2016010474A patent/MX2016010474A/es unknown
- 2015-02-10 BR BR112016018604A patent/BR112016018604A2/pt not_active Application Discontinuation
- 2015-02-10 EP EP15703288.9A patent/EP3105209B1/en active Active
- 2015-02-10 AU AU2015217788A patent/AU2015217788B2/en not_active Ceased
- 2015-02-10 CR CR20160361A patent/CR20160361A/es unknown
- 2015-02-11 TW TW104104623A patent/TWI666202B/zh not_active IP Right Cessation
- 2015-02-11 UY UY0001035991A patent/UY35991A/es not_active Application Discontinuation
-
2016
- 2016-07-14 IL IL246785A patent/IL246785A0/en unknown
- 2016-08-10 PH PH12016501581A patent/PH12016501581A1/en unknown
- 2016-08-11 DO DO2016000208A patent/DOP2016000208A/es unknown
- 2016-08-11 CL CL2016002033A patent/CL2016002033A1/es unknown
- 2016-08-11 SV SV2016005257A patent/SV2016005257A/es unknown
-
2018
- 2018-03-16 US US15/923,895 patent/US10442772B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CL2016002033A1 (es) | 2017-03-31 |
| AU2015217788A1 (en) | 2016-08-04 |
| CU24410B1 (es) | 2019-05-03 |
| MX2016010474A (es) | 2016-10-31 |
| UY35991A (es) | 2015-09-30 |
| PE20170143A1 (es) | 2017-03-19 |
| EA201691590A1 (ru) | 2017-02-28 |
| SV2016005257A (es) | 2018-10-02 |
| EP3105209B1 (en) | 2019-08-21 |
| EP3105209A1 (en) | 2016-12-21 |
| WO2015121210A1 (en) | 2015-08-20 |
| BR112016018604A2 (pt) | 2017-08-08 |
| KR20160115991A (ko) | 2016-10-06 |
| CA2939026A1 (en) | 2015-08-20 |
| US10442772B2 (en) | 2019-10-15 |
| CN106573897A (zh) | 2017-04-19 |
| DOP2016000208A (es) | 2016-09-15 |
| AU2015217788B2 (en) | 2019-06-27 |
| JP2017505790A (ja) | 2017-02-23 |
| PH12016501581A1 (en) | 2017-02-06 |
| IL246785A0 (en) | 2016-08-31 |
| TW201613874A (en) | 2016-04-16 |
| CU20160120A7 (es) | 2016-12-23 |
| JP6534675B2 (ja) | 2019-06-26 |
| CN106573897B (zh) | 2019-09-24 |
| AP2016009371A0 (en) | 2016-08-31 |
| TWI666202B (zh) | 2019-07-21 |
| EA031655B1 (ru) | 2019-02-28 |
| US20190062285A1 (en) | 2019-02-28 |
| SG11201605810WA (en) | 2016-08-30 |
| US20170197921A1 (en) | 2017-07-13 |
| US9957235B2 (en) | 2018-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000208A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| CY1124855T1 (el) | 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| UY37461A (es) | 1,2,4 – triazolonas 2,4,5 trisustituida | |
| CR20160337A (es) | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b | |
| NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| MX386935B (es) | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| UY36702A (es) | Piridinas sustituidas y métodos de uso | |
| CR20160433A (es) | Nuevos compuestos | |
| ECSP16074478A (es) | Compuestos novedosos | |
| DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| DOP2017000146A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| UY37973A (es) | Derivados de indol macrocíclicos | |
| UY37250A (es) | Derivados macrocíclicos de indol | |
| DOP2016000268A (es) | Compuestos de azol amidosustituidos como inhibidores de tnks1 y/o tnks2 | |
| CR20160316A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. |